查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088480

直接抗病毒藥物市場：2026-2032年全球市場預測（按產品類型、治療領域、給藥途徑、最終用戶和分銷管道分類）

Direct-acting Antiviral Drug Market by Product Type, Therapeutic Area, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，直接作用抗病毒藥物市場將成長至 349.2 億美元，複合年成長率為 14.10%。

主要市場統計數據
基準年 2025 138.7億美元
預計年份：2026年 157.9億美元
預測年份 2032 349.2億美元
複合年成長率 (%) 14.10%

直接抗病毒藥物（DAA）透過針對病毒複製的特定階段，而非主要依賴廣泛的免疫調節，正在徹底改變病毒性疾病的治療方式。在C型肝炎病毒的治療中，最新的DAA療法已成為精準抗病毒治療的標準，世界衛生組織（WHO）報告稱，如果患者接受適當的治療，治癒率可超過95%。

市場需求主要源自於明確的公共衛生需求。世界衛生組織估計，到2022年，全球約有5,000萬人患有慢性C型肝炎，新增感染病例約100萬例。這導致市場對價格合理的口服治療方案、簡化的診斷方法、分散式治療以及能夠將服務範圍擴大到專科醫療機構以外的採購模式的需求持續成長。

DAA領域的變革性變化

直接抗病毒藥物（DAA）領域最顯著的轉變是從複雜的基於干擾素的療法轉向短劑量、全口服、完全基因型標靶的治療方案。這縮短了治療療程，提高了耐受性，並使其在基層醫療、矯正醫學、減害措施和國家級根除計畫中得到更廣泛的應用。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過患者發現、臨床決策支援、藥物安全監測和供應計劃，對直接抗病毒藥物 (DAA) 的價值鏈產生日益顯著的影響。 AI 驅動的風險分層有助於醫療系統從具有風險因素（例如注射吸毒史、肝酵素水平異常、透析史、監禁史或出生隊列）的人群中識別出未確診的丙型肝炎患者。

關於DAA實施的關鍵區域見解

亞太地區是重點關注區域，因為該地區患者人數眾多，學名藥的可及性不斷提高，且主導政府都在積極推進丙型肝炎根除舉措。中國、印度、日本、澳洲和韓國正在以不同的速度推進篩檢和治療途徑，其中印度在提供價格合理的活性成分和非專利藥方面發揮核心作用。世衛組織針對西太平洋和東南亞地區的C型肝炎策略持續強調擴大診斷範圍、擴大治療範圍，並將病毒性肝炎服務納入基層醫療。

策略市場關鍵群分析

東協市場的特點是報銷機制多樣化、診斷能力不斷提高，以及對價格合理的泛基因型療法的迫切需求。在自付費用高、專科醫生短缺影響醫療服務可近性的地區，這一趨勢尤其顯著。海灣合作理事會（GCC）憑藉其資助國家醫療改革計畫、醫院現代化以及病毒性肝炎和相關肝病綜合篩檢措施的能力，被定位為高階醫療服務叢集。

來自主要國家的商業策略洞見

美國仍然是DAA（直接抗病毒藥物）的商業性市場，這得益於先進的診斷技術和廣泛的臨床專業知識，但成本效益、保險公司的批准以及服務不足人群等因素仍然影響著治療的可及性。在加拿大，獲得公共衛生服務和省級醫保報銷是關鍵因素；而在拉丁美洲，墨西哥和巴西是主要市場，公共採購、國家肝炎控制計劃和公立醫院網路都會影響需求。

為行業領導者提供的實用建議

產業領導者需要將直接抗病毒藥物（DAA）策略與整個治療流程相協調，篩檢和確診檢測、治療啟動、藥物依從性以及治療後追蹤等各個環節。最大的機會將來自於簡化基層醫療的就醫途徑、開展減害計畫、提供矯正性治療、將治療融入社區實踐以及與政府合作實現肝炎根除目標。

調查方法

本執行摘要基於權威公共衛生、監管、臨床和行業資訊來源的二手研究，包括更新的全球疾病負擔數據、治療指南、產品核可、採購趨勢以及關於 DAA 有效性的同行評審證據。

結論

直接抗病毒藥物（DAA）市場具有罕見的綜合優勢，包括高臨床療效、明確的公共衛生需求以及擴大可及性的潛力。在C型肝炎的適當治療中，DAA的治癒率超過95%，因此它仍然是感染疾病治療領域最具影響力的藥物類別之一，也是實現根除病毒性肝炎目標的關鍵工具。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 直接作用抗病毒藥物市場：依產品類型分類

  • 品牌藥品
  • 學名藥

第8章 直接作用抗病毒藥物市場：依治療領域分類

  • C型肝炎病毒（HCV）抗病毒藥物
    • NS5A抑制劑
    • NS5B聚合酵素抑制劑
    • NS3/4A蛋白酶抑制劑
  • 乙型肝炎病毒（HBV）抗病毒藥物
    • 衣殼形成調節因子
    • 入侵抑制劑
    • 基於RNA干擾（RNAi）的藥物
  • HIV直接抗病毒藥物
    • 蛋白酶抑制劑
    • 整合酶/鏈轉移抑制劑（INSTIs）
    • 逆轉錄酶抑制劑
  • 用於治療流感和呼吸道病毒的直接抗病毒藥物（DAAs）

第9章：直接作用抗病毒藥物市場：依給藥途徑分類

  • 口服直接抗病毒藥物
  • 注射用直接抗病毒藥物
  • 靜脈注射抗病毒藥物
  • 長效緩釋製劑

第10章 直接作用抗病毒藥物市場：依最終用戶分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章 直接作用抗病毒藥物市場：依分銷管道分類

  • 線上
  • 離線

第12章 直接作用抗病毒藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 直接作用抗病毒藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 直接作用抗病毒藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Beximco Pharmaceuticals Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-032A67D91452

The Direct-acting Antiviral Drug Market is projected to grow by USD 34.92 billion at a CAGR of 14.10% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.87 billion
Estimated Year [2026] USD 15.79 billion
Forecast Year [2032] USD 34.92 billion
CAGR (%) 14.10%

Direct-acting antiviral drugs are reshaping viral disease management by targeting specific steps in viral replication rather than relying mainly on broad immune modulation. In hepatitis C virus care, modern DAA regimens have become the benchmark for precision antiviral therapy, with the World Health Organization reporting cure rates above 95% when patients receive appropriate treatment.

Market momentum is supported by a clear public health mandate. WHO estimates that about 50 million people were living with chronic hepatitis C infection in 2022, with approximately 1 million new infections occurring that year. This creates sustained demand for affordable oral regimens, simplified diagnostics, treatment decentralization, and procurement models that expand access beyond specialist centers.

Transformative Shifts in the DAA Landscape

The most important shift in the direct-acting antiviral drug landscape is the move from complex interferon-based therapy to short-course, all-oral, pan-genotypic regimens. This has reduced treatment duration, improved tolerability, and enabled broader use in primary care, correctional health, harm-reduction settings, and national elimination programs.

Competition is also shifting from clinical efficacy alone to access, adherence, and system-level execution. As patents expire and licensed generic supply expands in many low- and middle-income markets, manufacturers and public health buyers are increasingly focused on price sustainability, diagnostic linkage, resistance monitoring, and real-world treatment completion.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing the DAA value chain through patient finding, clinical decision support, pharmacovigilance, and supply planning. AI-enabled risk stratification can help health systems identify undiagnosed hepatitis C among people with historical injection drug use, abnormal liver enzymes, dialysis exposure, incarceration history, or birth-cohort risk.

The cumulative impact is operational rather than speculative. AI can shorten the gap between screening and treatment initiation, forecast demand for national procurement, detect safety signals from real-world data, and support adherence interventions. However, industry leaders must pair AI deployment with validated datasets, privacy safeguards, explainable models, and clinical oversight to avoid bias in underserved populations.

Key Regional Insights for DAA Adoption

Asia-Pacific represents a high-priority region because of large patient pools, expanding generic availability, and government-backed hepatitis elimination initiatives. China, India, Japan, Australia, and South Korea are advancing screening and treatment pathways at different speeds, with India playing a central role in affordable active pharmaceutical ingredient and generic formulation supply. WHO's Western Pacific and South-East Asia regional hepatitis strategies continue to emphasize diagnosis expansion, treatment scale-up, and integration of viral hepatitis services into primary care.

North America remains a high-value market driven by established reimbursement, advanced diagnostics, and strong specialist networks, although treatment gaps persist among uninsured populations, people who inject drugs, and incarcerated individuals. Latin America is improving access through public procurement and regional health programs, with Brazil and Mexico serving as important demand centers where national treatment guidelines and public-sector purchasing shape DAA availability.

Europe benefits from structured elimination strategies, centralized health systems, and mature clinical guidelines, but progress varies by country and by linkage-to-care capacity. The Middle East, particularly GCC markets, shows rising investment in specialty medicines and national screening supported by broader health transformation programs. Africa has the greatest access challenge, where disease burden, limited diagnostics, and financing constraints make low-cost regimens, simplified testing, and decentralized care essential to improve treatment coverage.

Key Group Insights Across Strategic Markets

ASEAN markets are characterized by diverse reimbursement systems, growing diagnostic capacity, and significant need for affordable pan-genotypic therapy, particularly where out-of-pocket costs and limited specialist coverage affect linkage to care. The GCC is positioned as a premium access cluster, supported by national health transformation programs, hospital modernization, and the ability to fund broad screening initiatives for viral hepatitis and related liver disease.

The European Union provides one of the most structured policy environments for DAA access, with strong regulatory oversight, established health technology assessment pathways, and cross-country evidence generation. BRICS countries combine high patient volumes with expanding domestic pharmaceutical capabilities, making them central to large-scale treatment access and generic competition. G7 countries continue to shape clinical standards, pharmacovigilance expectations, and premium innovation pathways, while NATO member states overlap with many high-income procurement systems that prioritize resilient medicine supply chains, continuity of essential therapies, and health security preparedness.

Key Country Insights for Commercial Strategy

The United States remains a commercially important DAA market, supported by advanced diagnostics and broad clinical expertise, but affordability, payer authorization, and underserved populations continue to shape treatment uptake. Canada emphasizes public health access and provincial reimbursement, while Mexico and Brazil are key Latin American markets where public procurement, national hepatitis programs, and public hospital networks influence demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature treatment pathways supported by specialist care networks, national guidelines, and established reimbursement processes, while Russia represents a large patient opportunity with access shaped by domestic policy, registration requirements, and procurement dynamics. China combines large disease prevalence with expanding local innovation and volume-based purchasing, while India is a major access market and global generic supplier. Japan, Australia, and South Korea are advanced markets with strong screening infrastructure, high clinical standards, and ongoing elimination priorities aligned with international viral hepatitis targets.

Actionable Recommendations for Industry Leaders

Industry leaders should align DAA strategy with the full care cascade: screening, confirmatory testing, treatment initiation, adherence, and post-treatment follow-up. The strongest opportunities will come from simplifying access in primary care, integrating treatment into harm-reduction programs, correctional health, and community clinics, and partnering with governments on hepatitis elimination targets.

Organizations should also strengthen real-world evidence programs, support affordable pricing models, and build supply resilience for active ingredients and finished-dose products. Digital patient navigation, AI-supported case finding, and collaboration with laboratories can reduce loss to follow-up and improve measurable cure outcomes. Leaders should prioritize ethical data use, pharmacovigilance readiness, and locally adapted access models to improve both clinical impact and long-term market relevance.

Research Methodology

This executive summary is developed using secondary research from authoritative public health, regulatory, clinical, and industry sources, including global disease burden updates, treatment guidelines, product approvals, procurement trends, and peer-reviewed evidence on DAA effectiveness.

The analysis triangulates epidemiology, access dynamics, regional policy signals, competitive behavior, and technology adoption to identify market direction. Insights are validated through consistency checks across public datasets, clinical guidance, regulatory information, and market-access evidence, with emphasis on verifiable trends rather than unsupported forecasts, market sizing, or market share estimates.

Conclusion

The direct-acting antiviral drug market is defined by a rare combination of high clinical efficacy, clear public health demand, and expanding access potential. With cure rates above 95% for appropriate hepatitis C treatment, DAAs remain one of the most impactful therapeutic classes in infectious disease and a critical tool for achieving viral hepatitis elimination objectives.

Future leadership will depend on more than product performance. Organizations that combine affordable access, evidence generation, AI-enabled patient identification, reliable supply, and region-specific partnerships will be best positioned to support elimination goals while sustaining long-term relevance in direct-acting antiviral therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Direct-acting Antiviral Drug Market, by Product Type

  • 7.1. Branded Drugs
  • 7.2. Generic Drugs

8. Direct-acting Antiviral Drug Market, by Therapeutic Area

  • 8.1. Hepatitis C Virus (HCV) Antivirals
    • 8.1.1. NS5A Inhibitors
    • 8.1.2. NS5B Polymerase Inhibitors
    • 8.1.3. NS3/4A Protease Inhibitors
  • 8.2. Hepatitis B Virus (HBV) Antivirals
    • 8.2.1. Capsid Assembly Modulators
    • 8.2.2. Entry Inhibitors
    • 8.2.3. RNA Interference (RNAi)-Based Agents
  • 8.3. HIV Direct-Acting Antivirals
    • 8.3.1. Protease Inhibitors
    • 8.3.2. Integrase Strand Transfer Inhibitors (INSTIs)
    • 8.3.3. Reverse Transcriptase Inhibitors
  • 8.4. Influenza & Respiratory Virus DAAs

9. Direct-acting Antiviral Drug Market, by Route of Administration

  • 9.1. Oral Direct-Acting Antivirals
  • 9.2. Injectable DAAs
  • 9.3. Intravenous DAAs
  • 9.4. Long-Acting Depot Formulations

10. Direct-acting Antiviral Drug Market, by End User

  • 10.1. Home Healthcare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Direct-acting Antiviral Drug Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Direct-acting Antiviral Drug Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Direct-acting Antiviral Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Direct-acting Antiviral Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Beximco Pharmaceuticals Ltd.
  • 16.3. Bristol-Myers Squibb Company
  • 16.4. Cipla Limited
  • 16.5. Dr. Reddy's Laboratories Ltd.
  • 16.6. Gilead Sciences, Inc.
  • 16.7. GlaxoSmithKline plc
  • 16.8. Hetero Labs Limited
  • 16.9. Johnson & Johnson
  • 16.10. Lupin Limited
  • 16.11. Merck & Co., Inc.
  • 16.12. Novartis AG
  • 16.13. Pfizer Inc.
  • 16.14. Regeneron Pharmaceuticals, Inc.
  • 16.15. Roche Holding AG
  • 16.16. Sun Pharmaceutical Industries Limited
  • 16.17. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS C VIRUS (HCV) ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS C VIRUS (HCV) ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEPATITIS C VIRUS (HCV) ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NS5A INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NS5A INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NS5A INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NS5B POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NS3/4A PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEPATITIS B VIRUS (HBV) ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATITIS B VIRUS (HBV) ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEPATITIS B VIRUS (HBV) ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAPSID ASSEMBLY MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAPSID ASSEMBLY MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAPSID ASSEMBLY MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA INTERFERENCE (RNAI)-BASED AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA INTERFERENCE (RNAI)-BASED AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA INTERFERENCE (RNAI)-BASED AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIV DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIV DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA & RESPIRATORY VIRUS DAAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA & RESPIRATORY VIRUS DAAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA & RESPIRATORY VIRUS DAAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL DIRECT-ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLE DAAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTABLE DAAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INJECTABLE DAAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS DAAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS DAAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS DAAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LONG-ACTING DEPOT FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LONG-ACTING DEPOT FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG-ACTING DEPOT FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS (HCV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS B VIRUS (HBV) ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV DIRECT-ACTING ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUT